ea0090p29 | Calcium and Bone | ECE2023
Palermo Andrea
, Khan Aliya
, Rubin Mishaela
, Schwarz Peter
, Shoback Dolores M.
, Gagnon Claudia
, Cetani Filomena
, Clarke Bart L.
, Tsourdi Elena
, Kohlmeier Lynn
, Sikjaer Tanja
, M Kaiser Stephanie
, Lai Bryant
, Le John
, Ukena Jenny
, Sibley Christopher
, Shu Aimee
, An Xubei
, Noori Wahidullah
, Smith Alden
, Vokes Tamara J.
Background: Individuals with hypoparathyroidism often experience a range of symptoms associated with reduced health-related quality of life (HRQoL) and work productivity. Conventional therapy aims to alleviate hypocalcemia and acute symptoms but fails to restore normal parathyroid hormone (PTH) physiology or improve HRQoL. In the PaTHway trial, 79% of participants treated with TransCon PTH vs. 5% placebo (P<0.0001) met the primary efficacy endpoint (normal serum c...